| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 84.57% | 86.06% | 85.93% | 81.79% | — | — |
| Operating Margin | -59.68% | -122.88% | -292.53% | -22.15% | — | — |
| EBITDA Margin | -58.29% | -120.35% | -288.74% | -18.94% | — | — |
| Net Margin | -86.88% | -102.09% | -318.93% | 44.68% | — | — |
| Current Ratio | 2.80 | 2.02 | 1.42 | 0.14 | 0.33 | — |
| Quick Ratio | 2.54 | 1.63 | 1.25 | -0.44 | 0.33 | — |
| Debt / Equity | -0.98 | -0.85 | 0.00 | — | — | — |
| ROE | 115.85% | 116.03% | 227.61% | -41.75% | -28.52% | — |
| ROA | -111.03% | -125.34% | -229.50% | 27.44% | 1.90% | — |
| Asset Turnover | 1.28 | 1.23 | 0.72 | 0.61 | — | — |
| Book Value / Share | -0.89 | -1.02 | -2.76 | -42.85 | — | — |
TriSalus Life Sciences Inc. operates as a biopharmaceutical company focused on the development of innovative therapies in the treatment of cancer. The company primarily targets solid tumors, utilizing unique delivery technologies to improve the effectiveness and distribution of immunotherapies directly within tumors. By addressing issues related to vascular perfusion and immune suppression in tumor environments, TriSalus seeks to enhance outcomes for patients undergoing difficult cancer treatments. Notable in its portfolio is the company's proprietary Pressure-Enabled Drug Delivery (PEDD) technology, which plays a crucial role in facilitating better drug penetration and distribution. TriSalus Life Sciences actively collaborates with research institutions and healthcare providers to bring cutting-edge treatment options from clinical trials to commercial availability. Positioned within the biotechnology industry, the company's work significantly impacts oncological therapeutic strategies, offering potential advancements in cancer treatment modalities. Through its dedicated approach, TriSalus Life Sciences Inc. contributes to the broader life sciences market, aspiring to transform cancer care.